Mmetụta na-ekwe nkwa nke α-synuclein Ezubere Immunotherapy n'ịgwọ Ọrịa Ọrịa Parkinson Early

Maka Immediate Hapụ
Mgbasa ozi kọntaktị: Erica Halmstad
+ 1 414-276-2145
ehalmstad@movementdisorders.org

MILWAUKEE, WI, USA - Ndị ọrịa nwere ọrịa Parkinson n'oge (PD) bụ ndị ejiri prasinezumab gwọọ afọ abụọ, α-synuclein ezubere iche maka immunotherapy, hụrụ ọtụtụ ọganihu moto dị mma karịa ndị natara ọgwụgwọ na-egbu oge na prasinezumab, dị ka nnyocha e gosipụtara na MDS Virtual Congress 2021.

Mkpokọta nke α-synuclein bụ ihe a ma ama na-enye aka na ma sporadic na ezinụlọ PD pathogenesis. Ya mere, α-synuclein bụ ihe a na-achọsi ike na-eme ka ọrịa gbanwee maka ọgwụgwọ PD n'ọdịnihu.

N'ime ọmụmụ ihe a, Pagano et al., jiri usoro ọgwụgwọ monoclonal antibody, prasinezumab, nke e mere iji kwado α-synuclein, iji gwọọ ndị ọrịa nwere PD n'oge. A na-enye ndị ọrịa prasinezumab kwa izu anọ maka afọ abụọ ma ọ bụ placebo maka izu 52 na-esote ọgwụgwọ prasinezumab na-egbu oge maka izu 52 fọdụrụnụ. A na-enyocha ihe mgbaàmà moto site na iji MDS-UPDRS Nkebi III ma jiri ya tụnyere akara akara.

Eng-King Tan, Senior Consultant Neurologist na Singapore General Hospital na prọfesọ na Duke-NUS Medical School, kwuru banyere ọmụmụ a, "Nsonaazụ mbụ nke nyocha mmalite nke prasinezumab bụ ihe na-akpali akpali n'ihi na ndị ọrịa PD na-emeso prasinezumab maka afọ abụọ na mmalite mmalite otu na-egosi na ọ na-eme nke ọma karịa ndị nọ na-egbu oge-mgbochi nke otu afọ ka bụ otu n'ime otu afọ. na ọ nwere mmetụta na-agbanwe ọrịa, nchọpụta mbụ na-enye mkpali iji mee nyocha na ule ndị ọzọ iji chọpụta ịdị irè ya na nchekwa ya n'ime ogologo oge ma na-atụkwa aro na immunotherapy bụ ụzọ ọgwụgwọ nwere ike isi mee PD. "

Onye dere akwụkwọ a bụ Roche n'ọrụ.

###

Banyere MDS Virtual Congress 2021: Ndị sonyere nzukọ na-ezukọ iji mụta nchoputa nyocha kachasị ọhụrụ yana nhọrọ ọgwụgwọ ọgbara ọhụrụ na nsogbu mmegharị, gụnyere ọrịa Parkinson. N'ime ndị dibịa 9,000, ndị ọkà mmụta sayensị na ndị ọkachamara ahụike sitere na mba 100 ga-esonye ihe fọrọ nke nta ka ọ bụrụ ilele ihe karịrị awa 30 nke ọdịnaya mmụta yana abtracts sayensị 1,300 nke ndị ọrụ ibe si gburugburu ụwa nyefee.

Banyere International Parkinson and Movement Disorder Society: International Parkinson and Movement Disorder Society (MDS), otu mba ụwa nke karịrị 11,000 ụlọ ọgwụ, ndị ọkà mmụta sayensị, na ndị ọkachamara ahụike ndị ọzọ, raara onwe ha nye iji kwalite nlekọta ndị ọrịa site na agụmakwụkwọ na nyocha. Maka ozi ndị ọzọ gbasara MDS, gaa na www.movementdisorders.org.